Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Debt (2018 - 2022)

Historic Total Debt for Lipocine (LPCN) over the last 5 years, with Q1 2022 value amounting to $1.5 million.

  • Lipocine's Total Debt fell 6896.49% to $1.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.5 million, marking a year-over-year decrease of 6896.49%. This contributed to the annual value of $2.3 million for FY2021, which is 5866.45% down from last year.
  • As of Q1 2022, Lipocine's Total Debt stood at $1.5 million, which was down 6896.49% from $2.3 million recorded in Q4 2021.
  • Lipocine's 5-year Total Debt high stood at $10.3 million for Q4 2018, and its period low was $1.5 million during Q1 2022.
  • Moreover, its 5-year median value for Total Debt was $6.4 million (2020), whereas its average is $6.7 million.
  • In the last 5 years, Lipocine's Total Debt crashed by 567.77% in 2019 and then tumbled by 6896.49% in 2022.
  • Quarter analysis of 5 years shows Lipocine's Total Debt stood at $10.3 million in 2018, then tumbled by 30.33% to $7.1 million in 2019, then fell by 21.79% to $5.6 million in 2020, then tumbled by 58.66% to $2.3 million in 2021, then crashed by 35.86% to $1.5 million in 2022.
  • Its Total Debt stands at $1.5 million for Q1 2022, versus $2.3 million for Q4 2021 and $3.1 million for Q3 2021.